The US Patent and Trademark Office (USPTO) has accepted Orgenesis' diabetes technology patent application.

The company said the technology ideal for insulin depended diabetes mellitus (IDDM) is beta cell replacement.

The technology uses patient’s own mature liver tissue to generate functional insulin-producing autologous cells by inducing developmental redirection to treat diabetes.

Orgenesis CEO Jacob BenArie said the company’s efforts in the coming months are focused on moving towards clinical trials aimed at ensuring the efficacy of the treatment.